Bausch Health Companies (NYSE: BHC)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Bausch Health Companies Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Bausch Health Companies Company Info
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.
News & Analysis
The company won a big patent fight with a generic-drug maker.
The company's exchange offer for existing senior notes appears to be going well.
Investors liked that the company was able to restructure some long-term debt.
Investors are increasingly realizing the scope of the turnaround project CEO Thomas Appio has on his plate.
A patent-court loss sent investors scurrying to the exits.
The worst-case scenario for a stock is that you become a bag holder and the stock goes to zero. Here's how to avoid that fate.
An abrupt shake-up in the board of directors has investors piling into this healthcare stock today.
The company shocked investors with its loss, although today may also be a major capitulation for the stock.
BHC earnings call for the period ending October 2, 2021.
BHC earnings call for the period ending June 30, 2021.
BHC earnings call for the period ending December 31, 2020.
BHC earnings call for the period ending September 30, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.